Arcus Biosciences said Wednesday that a two-drug combination that includes an anti-TIGIT antibody delivered “encouraging clinical activity” following a preliminary look at a clinical trial of patients with lung cancer.
Beyond a verbal description of the interim study results, however, the Hayward, Calif.-based biotech isn’t saying much about its closely tracked TIGIT immunotherapy, called domvanalimab. Gilead Sciences has an option to license domvanalimab, but is deferring a decision until later this year, Arcus said Wednesday.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
